ArticlePloS one2025
Effects and predictors of intravenous lidocaine infusion for patients with fibromyalgia.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Effect of Intravenous Lidocaine Treatment on Sleep and Quality of Life in Fibromyalgia: An Observational Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFibromyalgia is a chronic pain condition characterised by widespread pain. The current treatment primarily focuses on self-management and symptomatic relief. IV lidocaine infusion is the most performed procedure in the UK that is offered after conventional therapy has failed. We aim to identify the predictors of response to systemic lidocaine to enable targeted treatment for individuals who are more likely to benefit.
methodsThis study adheres to the RECORD guidelines for reporting studies using routinely collected observational data. It was conducted retrospectively and employed data derived from clinical records of patients who received standard care. Adult patients who had completed questionnaires and quantitative sensory testing (QST) before IV lidocaine infusion were included. We collected data consecutively from 132 patients, including 24 men and 108 women. Responders were defined as patients who experienced a pain reduction of 50% or greater lasting for at least three weeks following an IV lidocaine infusion at a dose of 5 mg/kg.
resultsWe identified 22% of patients as responders. Our findings indicate a notable gender disparity in the number of responders, with a response rate of 25.9% observed in female patients compared to 4.2% in male patients (p = 0.02). Functional impairment in the revised fibromyalgia impact questionnaire was higher in female patients than male patients (22.6 ± 5.8 vs 19.8 ± 7.7, p = 0.043). Responders were younger (42.7 ± 11.2 vs 49.4 ± 11.4, p = 0.003), had shorter pain duration in years (10.0 ± 6.1 vs 14.1 ± 9.3, p = 0.015), and lower weekly pain scores (7.8 ± 1.7 vs 8.5 ± 1.4, p = 0.014). No significant difference in QST parameters or loss/gain phenotypes was observed between responders and non-responders. A normal QST was identified in 25% of responders and 16% of non-responders. Consequently, QST alone could not predict the response to systemic lidocaine infusion.
conclusionsIV lidocaine infusion proves effective, especially for younger female patients, which should be added to conventional therapies for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.